These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 33651913)

  • 61. Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery.
    Gaudy-Marqueste C; Dussouil AS; Carron R; Troin L; Malissen N; Loundou A; Monestier S; Mallet S; Richard MA; Régis JM; Grob JJ
    Eur J Cancer; 2017 Oct; 84():44-54. PubMed ID: 28783540
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.
    Gibney GT; Gauthier G; Ayas C; Galebach P; Wu EQ; Abhyankar S; Reyes C; Guérin A; Yim YM
    Cancer Med; 2015 Aug; 4(8):1205-13. PubMed ID: 25991583
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prognostic factors for overall survival after radiosurgery for brain metastases from melanoma.
    Marcus DM; Lowe M; Khan MK; Lawson DH; Crocker IR; Shelton JW; Melton A; Maynard N; Delman KA; Carlson GW; Rizzo M
    Am J Clin Oncol; 2014 Dec; 37(6):580-4. PubMed ID: 23428955
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Metastatic melanoma: prognostic factors and survival in patients with brain metastases.
    Frinton E; Tong D; Tan J; Read G; Kumar V; Kennedy S; Lim C; Board RE
    J Neurooncol; 2017 Dec; 135(3):507-512. PubMed ID: 28819707
    [TBL] [Abstract][Full Text] [Related]  

  • 65. BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases.
    Xu Z; Lee CC; Ramesh A; Mueller AC; Schlesinger D; Cohen-Inbar O; Shih HH; Sheehan JP
    J Neurosurg; 2017 Mar; 126(3):726-734. PubMed ID: 27203149
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy.
    Tio M; Wang X; Carlino MS; Shivalingam B; Fogarty GB; Guminski AD; Lo S; Hong AM; Menzies AM; Long GV
    Pigment Cell Melanoma Res; 2018 Jul; 31(4):509-515. PubMed ID: 29277979
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Systematic literature review and meta-analysis of clinical outcomes and prognostic factors for melanoma brain metastases.
    Tan XL; Le A; Scherrer E; Tang H; Kiehl N; Han J; Jiang R; Diede SJ; Shui IM
    Front Oncol; 2022; 12():1025664. PubMed ID: 36568199
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalities.
    Chorti E; Kebir S; Ahmed MS; Keyvani K; Umutlu L; Kanaki T; Zaremba A; Reinboldt-Jockenhoefer F; Knispel S; Gratsias E; Roesch A; Ugurel S; Scheffler B; Schadendorf D; Livingstone E; Meier F; Glas M; Zimmer L
    Eur J Cancer; 2021 May; 148():395-404. PubMed ID: 33789203
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Predictive value of a nomogram for melanomas with brain metastases at initial diagnosis.
    Liu H; Xu YB; Guo CC; Li MX; Ji JL; Dong RR; Zhang LL; He XX
    Cancer Med; 2019 Dec; 8(18):7577-7585. PubMed ID: 31657530
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Economic and health care resource utilization burden of central nervous system metastases in patients with metastatic melanoma.
    Tawbi H; Bartley K; Seetasith A; Kent M; Lee J; Burton E; Haydu L; McKenna E
    J Manag Care Spec Pharm; 2022 Mar; 28(3):342-353. PubMed ID: 35199578
    [No Abstract]   [Full Text] [Related]  

  • 71. Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features.
    Raizer JJ; Hwu WJ; Panageas KS; Wilton A; Baldwin DE; Bailey E; von Althann C; Lamb LA; Alvarado G; Bilsky MH; Gutin PH
    Neuro Oncol; 2008 Apr; 10(2):199-207. PubMed ID: 18287337
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies.
    Vosoughi E; Lee JM; Miller JR; Nosrati M; Minor DR; Abendroth R; Lee JW; Andrews BT; Leng LZ; Wu M; Leong SP; Kashani-Sabet M; Kim KB
    BMC Cancer; 2018 Apr; 18(1):490. PubMed ID: 29703161
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Radiosurgery in the management of brain metastasis: a retrospective single-center study comparing Gamma Knife and LINAC treatment.
    Tuleasca C; Negretti L; Faouzi M; Magaddino V; Gevaert T; von Elm E; Levivier M
    J Neurosurg; 2018 Feb; 128(2):352-361. PubMed ID: 28338441
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Significant survival improvements for patients with melanoma brain metastases: can we reach cure in the current era?
    Berger A; Bernstein K; Alzate JD; Mullen R; Silverman JS; Sulman EP; Donahue BR; Pavlick AC; Gurewitz J; Mureb M; Mehnert J; Madden K; Palermo A; Weber JS; Golfinos JG; Kondziolka D
    J Neurooncol; 2022 Jul; 158(3):471-480. PubMed ID: 35665462
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities?
    Gampa G; Vaidhyanathan S; Sarkaria JN; Elmquist WF
    Pharmacol Res; 2017 Sep; 123():10-25. PubMed ID: 28634084
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Melanoma brain metastases in Ireland: surgical and systemic considerations.
    O'Halloran PJ; Cleary A; Cryan JB; Beausang A; Brett FM; Caird J
    Br J Neurosurg; 2022 Apr; 36(2):236-240. PubMed ID: 33904364
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Synergic prognostic value of 3D CT scan subcutaneous fat and muscle masses for immunotherapy-treated cancer.
    Decazes P; Ammari S; Belkouchi Y; Mottay L; Lawrance L; de Prévia A; Talbot H; Farhane S; Cournède PH; Marabelle A; Guisier F; Planchard D; Ibrahim T; Robert C; Barlesi F; Vera P; Lassau N
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37678919
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Ipilimumab and Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone for Newly Diagnosed Melanoma Brain Metastases.
    Patel KR; Shoukat S; Oliver DE; Chowdhary M; Rizzo M; Lawson DH; Khosa F; Liu Y; Khan MK
    Am J Clin Oncol; 2017 Oct; 40(5):444-450. PubMed ID: 26017484
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases.
    Nardin C; Mateus C; Texier M; Lanoy E; Hibat-Allah S; Ammari S; Robert C; Dhermain F
    Melanoma Res; 2018 Apr; 28(2):111-119. PubMed ID: 29356789
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Impact of cranial stereotactic radiotherapy associated with immunotherapy with nivolumab and ipilimumab on overall survival in patients with melanoma brain metastases: a real-world evidence.
    de Castro DG; Teixeira CHA; Gondim GRM; Aguilar PB; Costa MASB; Jorge TWC; Morais Hanriot R
    Clin Transl Oncol; 2022 Sep; 24(9):1828-1830. PubMed ID: 35546648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.